Last month, PCI signed a deal to acquire Ajinomoto Althea, a subsidiary of Japan-based Ajinomoto. This acquisition is part of PCI’s investment strategy to enhance its manufacturing capabilities
This fixed-dose combo of Perjeta (pertuzumab) and Herceptin (trastuzumab), delivered via SC injection along with intravenous chemotherapy, offers a subcutaneous (SC) treatment option for human epidermal growth factor
This agreement designates Er-Kim as the distributor for the therapy in Azerbaijan, Armenia, Belarus, Georgia, Kyrgyzstan, Kazakhstan, Uzbekistan, Tajikistan, Russia, and Turkmenistan. The prescription medicine, Nerlynx, is intended
According to the company, Zevaskyn is the first and only autologous cell-based gene therapy. The FDA’s decision is supported by the outcomes from the pivotal randomised intrapatient-controlled multi-centre
This status is conferred by the European Commission following a positive opinion from the EMA Committee for orphan medicinal products and offers several benefits, including market exclusivity and
The acquisition enables Apnimed to advance the therapy through its joint venture (JV) with Japanese pharma company, Shionogi & Co. Desitin Arzneimittel will receive an upfront, future milestone
This initiative aims to harness biological and clinical insights, identify new drug targets, and create therapeutics for the oncology sector. The collaboration will leverage de-identified oncology data of
This recommendation facilitates treating the activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 years and above. The oral therapy is now accessible and funded in
This allosteric pan-mutant-selective phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor and degrader is poised to enter first-in-human trials in the second quarter of this year. According to the company, mutant
Effexor, a serotonin-noradrenaline reuptake inhibitor (SNRI), has shown promise in treating GAD in adults through a recent study in Japan. The Phase III trial, Study B2411367, confirmed venlafaxine’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.